The acylation stimulating protein pathway: Clinical implications

Clinical Biochemistry

Volumn 30, Issue 4, 1997, Pages 301-312

  Cianflone, Katherine ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Acylation stimulating protein; Adipose triglyceride synthesis; Complement C3a; Differentiation; Glucose transport

Indexed keywords

FATTY ACID; LIPOPROTEIN LIPASE; TRIACYLGLYCEROL;

ACYLATION; ADIPOSE TISSUE; CELL CULTURE; DIABETES MELLITUS; ESTERIFICATION; FATTY ACID METABOLISM; GLUCOSE METABOLISM; ISCHEMIC HEART DISEASE; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030910245     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(97)00011-8     Document Type: Article

References (125)

1. Dani C, Amri E, Bertrand BG, et al. Expression and regulation of pob24 and lipoprotein lipase genes during adipose conversion. J Cell Biochem 1990; 43: 103-10.
2. Ailhaud G, Grimaldi P, Négrel R. Cellular and molecular aspects of adipose tissue development. Annu Rev Nutr 1992; 12: 207-33.
3. Cook KS, Min HY, Johnson D, et al. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science 1987; 237: 402-5.
4. Jiang XC, Moulin P, Quinet E, et al. Mammalian adipose tissue and muscle are major sources of lipid transfer protein mRNA. J Biol Chem 1991; 266: 4631-9.
5. Zechner R, Moser R, Newman TC, Fried SK, Breslow JL. Apolipoprotein E gene expression in mouse 3T3-L1 adipocytes and human adipose tissue and its regulation by differentiation and lipid content. J Biol Chem 1991; 266: 10583-8.
6. Labrie F, Simard J, Luu-The V, et al. Expression of 3-beta-hydroxysteroid dehydrogenase delta-4-5 isomerase and 17-beta-hydroxysteroid dehydrogenase in adipose tissue. Intl J Obesity 1991; 15: 91-9.
7. Xu X, De Pergole G, Bjorntorp P. The effects of androgens on the regulation of lipolysis in adipose precursor cells. Endocrinology 1990; 126: 1229-34.
8. Labrie F. At the cutting edge: Intracrinology. Mol Cell Endocrinol 1991; 78: C113-8.
9. Cassis LA, Saye J, Peach MJ. Location and regulation of rat angiotensinogen messenger RNA. Hypertension 1988; 11: 591-6.
10. Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue: Regulation by obesity, weight loss, and relationship to lipoprotein lipase: J Clin Invest 1995; 95: 2111-9.
11. Petruschke TH, Hauner H. Tumor necrosis factor-α prevents the differentiation of human adipocyte precursor cells and causes delipidation of newly developed fat cells. J Clin Endo Metab 1993; 78(3): 742-7.
12. Spiegleman BM, Choy L, Hotamisligil GS, Graves RA, Tontona P. Regulation of adipocyte gene expression in differentiation and syndromes of obesity/diabetes. J Biol Chem 1993; 268: 6825-6.
13. Masuzaki H, Ogawa Y, Isse N, et al. Human obese gene expression: adipocyte-specific expression and regional differences in the adipose tissue. Diabetes 1995; 44: 855-8.
14. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269: 540-3.
15. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269: 543-6.
16. Cianflone K, Sniderman AD, Walsh MJ. Purification and characterization of acylation stimulating protein. J Biol Chem 1989; 264: 426-30.
17. Baldo A, Sniderman AD, St-Luce S, et al. The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J Clin Invest 1993; 92(3): 1543-57.
18. Baldo A, Sniderman AD, St-Luce S, Zhang XJ, Cianflone K. The signal transduction pathway of acylation stimulating protein: involvement of protein kinase C. J Lipid Res 1995; 36: 1415-26.
19. Schreiber RD, Muller-Eberhard HJ. Assembly of the cytolytic alternative pathway of complement from 11 isolated plasma proteins. J Exp Med 1978; 148: 1722-7.
20. Lesavre PH, Hugli TE, Esser AF, Muller-Eberhard HJ. The alternative pathway C3/C5 convertase: Chemical basis of factor B activation. J Immunol 1979; 123: 529-34.
21. Lesavre P, Muller-Eberhard HJ. Mechanism of action of factor D of the alternative complement pathway. J Exp Med 1978; 148(6): 1498-1509.
22. Muller-Eberhard HJ, Schreiber RD. Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol 1980; 29: 1-53.
23. Cianflone K, Roncari DAK, Maslowska M, et al. Adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis. Biochemistry 1994; 33: 9489-95.
24. Cianflone K, Murray I, Kalant D, Zhang Z, Sniderman AD. Structure-function analysis of human and recombinant acylation stimulating protein. Circulation 1996; 94(8): 1-347.
25. Cook KS, Groves GL, Min HY, Spiegelman BM. A developmentally regulated mRNA from 3T3 adipocytes encodes a novel serine protease homologue. Proc Natl Acad Sci USA 1985; 82: 6480-4.
26. White RT, Damm D, Hancock N, et al. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem 1992; 267: 9210-3.
27. Choy LN, Rosen BS, Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 1992; 267: 12736-41.
28. Flier JS, Cook KS, Usher P, Spiegelman BM. Severely impaired adipsin expression in genetic and acquired obesity. Science 1987; 237: 405-8.
29. Cianflone K, Maslowska M. Differentiation induced production of ASP in human adipocytes. Eur J Clin Invest 1995; 25: 817-25.
30. Maslowska M, Scantlebury T, Germinario R, Cianflone K. Acute in vitro production of ASP in differentiated adipocytes. J Lipid Res 1997; 38: 21-30.
31. Cianflone K, Vu H, Walsh M, Baldo A, Sniderman AD. The metabolic response of ASP to an oral fat load. J Lipid Res 1989; 30: 1727-33.
32. Lamb RG, Fallon HJ. Glycerolipid formation from sn-glycerol-3-phosphate by rat liver cell fractions. Biochim Biophys Acta 1974; 348: 166-78.
33. Mayorek N, Grinstein I, Bar-Tana J. Triacylglycerol synthesis in cultured rat hepatocytes: The rate limiting role of diacylglycerol acyltransferase. Eur J Biochem 1989; 182: 395-400.
34. Nimmo HG, Houston B. Rat adipose-tissue glycerolphosphate acyltransferase can be inactivated by cyclic AMP-dependent protein kinase. Biochem J 1978; 176: 607-10.
35. Haagsman HP, de Haas CGM, Geelen MJH, van Golde LMG. Regulation of triacylglycerol synthesis in the liver: Modulation of diacylglycerol acyltransferase activity in vitro. J Biol Chem 1982; 257: 10593-8.
36. Rebuffe-Scrive M, Krotkiewski M, Elfverson J, Bjorntorp P. Glucocorticoid hormone binding to human adipose tissue. Eur J Clin Invest 1985; 15: 267-71.
37. Sooranna S, Saggerson E. Studies on the role of insulin in the regulation of glyceride synthesis in rat epididymal adipose tissue. Biochem J 1975; 150: 441-51.
38. Kwiterovich PO Jr, Motevalli M, Miller M. Acylation-stimulatory activity in hyperapobetalipoproteinemic fibroblasts: enhanced cholesterol esterification with an additional serum basic protein, BPII. Proc Natl Acad Sci USA 1990; 87: 8980-4.
39. Kwiterovich PO Jr, Motevalli M. Inhibition of protein tyrosine kinase alters the effects of basic serum protein I on triacylglycerols and cholesterol differently in normal and hyperapoB fibroblasts. Arterio, Thromb & Vasc Biol 1995; 15(8): 1195-1203.
40. Parker RA, Gill BT, Sabrah T, Kirchgessner T. Functional activity of Acylation Stimulating Protein (ASP) and evidence for its identity as complement factor C3a-des-arg. Diabetes 1995; 44(Suppl I): 150A.
41. Germinario R, Sniderman AD, Manuel S, et al. Coordinate response of triacylglycerol synthesis and glucose transport by acylation stimulating protein. Metabolism 1993; 42(5): 574-80.
42. Abumrad NA, el-Magharabi MR, Amri EZ, Lopez F, Grimaldi PA. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiatin. Homology with human CD36. J Biol Chem 1993; 268: 17665-8.
43. Stump DD, Zhou SL, Berk PD. Comparison of plasma membrane FABP and mitochondrial isoform of aspartate amino transferase from rat liver. Am J Physiol 1993; 265: G894-902.
44. Yasruel Z, Cianflone K, Sniderman AD, et al. Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose tissue. Lipids 1991; 26(7): 495-9.
45. Walsh MJ, Sniderman AD, Cianflone K., et al. The effect of ASP on the adipocyte of the morbidly obese. J Surg Res 1989; 46: 470-3.
46. Maslowska M, Sniderman AD, Germinario R, Cianflone K. ASP stimulates glucose transport in cultured human adipocytes. Intl J Obesity 1997; 21: 261-266.
47. Tao Y, Cianflone K, Sniderman AD, Colby-Germinario SP, Germinario RJ. Acylation stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line. Biochim Biophys Acta 1997; 1344: 221-229.
48. Cianflone K, Maslowska M, Sniderman AD. Impaired response of fibroblasts in patients with hyperapobetalipoproteinemia to acylation stimulating protein. J Clin Invest 1990; 85: 722-30.
49. Kalant D, Zhang ZJ, Cianflone K, Sniderman AD. Specific binding of ASP to human fibroblasts and human adipocytes. Clin Invest Med 1995; 18(Suppl B): B10.
50. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Am Physiol Soc 1994; 74(4): 761-811.
51. Maslowska MH, Sniderman AD, MacLean LD, Cianflone K. Regional differences in triacylglycerol synthesis in adipose tissue. J Lipid Res 1993; 34(2): 219-28.
52. Edens NK, Fried SK, Krai JG, Hirsch J, Leibel RL. In vitro lipid synthesis in human adipose from three abdominal sites. Am J Physiol 1993; 265(28): E374-9.
53. Cianflone K, Kalant D, Marliss EB, Gougeon R, Sniderman AD. Response of plasma ASP to a prolonged fast. Intl J Obesity 1995; 19: 604-9.
54. Napolitano A, Lowell BB, Damm D, et al. Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass. Intl J Obesity 1994; 18: 213-20.
55. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metabolism 1982; 54(2): 254-60.
56. Krotkiewski M, Bjorntrop P, Sjöström L, Smith U. Impact of obesity on metabolism in men and women: Importance of regional adipose tissue distribution. J Clin Invest 1983; 72(3): 1150-62.
57. Kashiwagi A, Verso MA, Andrews J, et al. In vitro insulin resistance of human adipocytes isolated from subjects with noninsulin-dependent diabetes mellitus. J Clin Invest 1983; 72(4): 1246-54.
58. Kashiwagi A, Bogardus C, Lillioja S, et al. In vitro insensitivity of glucose transport and antilipolysis to insulin due to receptor and postreceptor abnormalities in obese Pima Indians with normal glucose tolerance. Metabolism 1984; 33(8): 772-7.
59. Ciaraldi TP, Kolterman OG, Olefsky JM. Mechanism of the postreceptor defect in insulin action in human obesity. J Clin Invest 1981; 68(4): 875-80.
60. Smith U. Effect of cell size on lipid synthesis by human adipose tissue in vitro. J Lipid Res 1971; 12: 65-70.
61. Bjorntorp P, Karlsson M. Triglyceride synthesis in human subcutaneous adipose tissue cells of different size. Eur J Clin Invest 1970; 1: 112-7.
62. Etherton ED, Aberle ED, Thompson EH, Allen CE. Effects of cell size and animal age on glucose metabolism in pig adipose tissue. J Lipid Res 1981; 22: 72-80.
63. Holm G, Jacobsson B, Bjorntorp P, Smith U. Effects of age and cell size on rat adipose tissue metabolism. J Lipid Res 1975; 16: 461-4.
64. Tokuyama K, Okuda H. Fatty acid synthesis in adipose tissues of physically trained rats in vivo. Am J Physiol 1983; 245: E8-13.
65. Hood RL, Trankina ML, Beitz DC, Best DJ. Insulin responsiveness in non-fa/fa and fa/fa Zucher rats: effects of adipocyte size. Intl J Obesity 1984; 8: 31-40.
66. Sniderman AD, Cianflone K, Eckel RH. Levels of acylation stimulating protein in obese women before and after moderate weight loss. Intl J Obesity 1991; 15(5): 333-6.
67. Brunzell JD, Schrott HQ, Motulsky AG, Bierman EL. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 1976; 25: 313-20.
68. Bjorntorp P, Bergman H, Varnauskas E. Plasma free fatty acid turnover rate in obesity. Acta Med Scand 1969; 185: 351-6.
69. Nestel PJ, Ishikawa T, Goldrick RB. Diminished plasma free fatty acid clearance in obese subjects. Metabolism 1978; 27(5): 589-97.
70. Lillioja S, Foley J, Bogardus C, Mott D, Howard BV. Free fatty acid metabolism and obesity in man: in vivo in vitro comparisons. Metabolism 1986; 35(6): 505-14.
71. Ostman J, Arner P, Engfeldt P, Kager L. Regional differences in the control of lipolysis in human adipose tissue. Metabolism 1979; 28: 1198-1205.
72. Smith U, Hammersten J, Bjorntorp P, Krai JG. Regional differences and effect of weight reduction on human fat cell metabolism. Eur J Clin Invest 1979; 9: 327-32.
73. Despres JP. The insulin resistance-dyslipidemia syndrome: the most prevalent cause of coronary artery disease? Can Med Assoc J 1993; 148: 1339-40.
74. Wing RR, Bunker CH, Kuller LH, Matthews KA. Insulin, body mass index, and cardiovascular risk factors in pre-menopausal women. Arteriosclerosis 1989; 9: 479-84.
75. Peiris AN, Struve MF, Kissebah AH. Relationship of body fat distribution to the metabolic clearance of insulin in premenopausal women. Intl J Obesity 1987; 11: 581-9.
76. Julien P, Gagné C, Murthy MRV, et al. Mutations of the lipoprotein lipase gene as a cause of dyslipidemias in the Québec population. Can J Cardiol 1994; 10(Suppl B): 54-60.
77. Babirak SP, Iverius PH, Fujimoto WY, Brunzell JD. Detection and characterization of the heterozygotic state for lipoprotein lipase deficiency. Atherosclerosis 1989; 9: 326-34.
78. Babirak SP, Brown BG, Brunzell JD. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler Thromb 1992; 12: 1176-83.
79. Nevin DN, Brunzell JD, Deeb SS. The LPL gene in individuals with familial combined hyperlipidemia and decreased LPL activity. Arterioscler Thromb 1994; 14: 869-73.
80. Gagné E, Genest J Jr, Zhang H, Clarke LA, Hayden MR. Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia. Arterioscler Thromb 1994; 14: 1250-7.
81. Rebuffé-Scrive M, Enk L, Crona N, et al. Fat cell metabolism in different regions in women. Effect of menstrual cycle, pregnancy, and lactation. J Clin Invest 1985; 75: 1973-6.
82. Lafontan M, Dang-Tran L, Berlan M. Alpha-adrenergic antilipolytic effect of adrenaline in human fat cells of the thigh: comparison with adrenaline responsiveness of different fat deposits. Eur J Clin Invest 1978; 9: 261-6.
83. Bolinder J, Kager L, Ostman J, Arner P. Differences at the receptor and post receptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes 1983; 32: 117-23.
84. Leibel R, Hirsch J. Site and sex related differences in adrenoreceptor status of human adipose tissue. J Clin Endocrinol 1987; 64: 1205-10.
85. Rebuffé-Scrive M, Anderson B, Olbe L, Bjorntorp P. Metabolism of adipose tissue in intraabdominal depots of nonobese men and women. Metabolism 1989; 38: 453-8.
86. Bjorntorp P. Portal adipose tissue as a generator of risk factors for cardiovascular disease and diabetics. Arteriosclerosis 1990; 10: 483-96.
87. Bjorntorp P. How should obesity be defined. J Intern Med 1990; 227: 147-9.
88. Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles PE. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 1989; 83: 1168-73.
89. Reynisdottir S, Eriksson M, Angelin B, Arner P. Impaired activation of adipocyte lipolysis in familial combined hyperlipidemia. J Clin Invest 1995; 95: 2161-9.
90. Olivecrona T, Bengtsson-Olivercrona G. Lipoprotein lipase and hepatic lipase. Curr Opin Lipidol 1990; 1: 222-30.
91. Peterson J, Bihain BE, Bengtsson-Olivecrona G, et al. Fatty acid control of lipoprotein lipase: a link between energy metabolism and lipid transport. Proc Natl Acad Sci USA 1990; 87: 909-13.
92. Marin P, Rebuffé-Scrive M, Bjorntorp P. Uptake of triglyceride fatty acids in adipose tissue in vivo in man. Eur J Clin Invest 1990; 20: 158-65.
93. Julius U, Leonhardt W, Noack D, et al. Pathogenetic role of adipose tissue lipase deficit for development of hypertriglyceridemia. Exp Clin Endocrinol 1989; 94: 187-93.
94. Olivecrona G, Olivecrona T. Triglyceride lipases and atherosclerosis. Curr Opin Lipidol 1995; 6: 291-305.
95. Watson TDG, Tan CE, McConnell M, et al. Measurement and physiological significance of lipoprotein and hepatic lipase activities in preheparin plasma. Clin Chem 1995; 41: 405-12.
96. Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T. Lipoprotein lipase mass and activity in plasma and increase after heparin are separate parameters with different relations to plasma lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15(8): 1086-93.
97. Seed M, Mailly F, Vallance D, et al. Lipoprotein lipase activity in patients with combined hyperlipidemia. Clin Invest 1994; 72: 100-6.
98. Taskinen MR. Postprandial lipemia and lipoprotein lipase. In: Atherosclerosis X. (Eds. Woodford FP, Davignon J, Sniderman AD), Pp. 758-62. Amsterdam: Elsevier, 1995.
99. Jansen H, Hop W, Van Tol A, Bruschke AVG, Birkenhager JC. Hepatic lipase and lipoprotein lipase are not major determinants of the low density lipoprotein subclass pattern in human subjects with coronary heart disease. Atherosclerosis 1994; 107: 45-54.
100. Campos H, Dreon DM, Krauss RM. Association of hepatic and lipoprotein lipase activities with changes in dietary composition and low density lipoprotein subclasses. J Lipid Res 1995; 36: 462-72.
101. St-Amand J, Després JP, Lemieux S, et al. Does lipoprotein or hepatic lipase activity explain the protective lipoprotein profile of premenopausal women. Metabolism 1995; 44: 491-8.
102. Jeppesen J, Hollenbeck CB, Zhou MY, et al. Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity, and postprandial lipemia. Arterioscler Thromb Vasc Biol 1995; 15: 320-4.
103. Carlson LA, Walldius G. Fatty acid incorporation into human adipose tissue in hypertriglyceridaemia. Eur J Clin Invest 1976; 6: 195-211.
104. Waldius G. Fatty acid incorporation into human adipose tissue (FIAT) in hypertriglyceridemia. Methodological, clinical and experimental studies. Acta Med Scand 1976; 591: 1-47.
105. Larsson B, Bjorntorp P, Holm J, et al. Adipocyte metabolism in endogenous hypertriglyceridemia. Metabolism 1975; 24(12): 1375-89.
106. Rubba P. Fractional fatty acid incorporation into human adipose tissue (FIAT) in hypertriglyceridemia. Atherosclerosis 1978; 29: 39-42.
107. Arner P, Engfeldt P, Östman J. Changes in the metabolism of fatty acids in adipose tissue in obese patients with primary hypertriacylglycerolemia. J Lipid Res 1982; 23: 422-7.
108. Saxena U, Witte LD, Goldberg IJ. Release of endothelial cell lipoprotein lipase by plasma lipoproteins and free fatty acids. J Biol Chem 1989; 264: 4349-55.
109. Karpe F, Olivecrona T, Walldius G, Hamsten A. Lipoprotein lipase in plasma after an oral fat load: relation to free fatty acids. J Lipid Res 1992; 33: 975-84.
110. Glaser DS, Yost TJ, Eckel RH. Preheparin lipoprotein lipolytic activities: relationship to plasma lipoproteins and postheparin lipolytic activities. J Lipid Res 1992; 33(2): 209-14.
111. Sniderman AD, Shapiro S, Marpole DG, et al. Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low-density (B) lipoproteins]. Proc Natl Acad Sci USA 1980; 77(1): 604-8.
112. Sniderman AD, Brown BG, Stewart FF, et al. From familial combined hyperlipidemia to hyperapoB: Unravelling overproduction of hepatic apoB lipoproteins. Curr Opin Lipidol 1992; 3(2): 137-42.
113. Kwiterovich PO Jr, Coresh J, Bachorik PS. Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (<50 years) and women (<60 years) with coronary artery disease. Am J Cardiol 1993; 71: 631-9.
114. Teng B, Sniderman AD, Soutar AK, Thompson GR. Metabolic basis of hyperapobetalipoproteinemia: turnover of apolipoprotein B in low-density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. J Clin Invest 1986; 77(3): 663-72.
115. Teng B, Thompson GR, Sniderman AD, et al. Composition and distribution of low-density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia and familial hypercholesterolemia. Proc Natl Acad Sci USA 1983; 80(21): 6662-6.
116. Goldstein JL, Schrott HG, Hazard WR, Blerman EL, Motulsky AG. Hyperlipidemia in coronary heart disease. II: genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52(7): 1544-68.
117. Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidemia workshop. Arteriosclerosis 1987; 7: 203-7.
118. Teng B, Forse A, Rodrigues MA, Sniderman A. Adipose tissue glyceride synthesis in patients with hyperapobetalipoproteinemia. Can J Physiol Pharmacol 1988; 66: 239-42.
119. Genest J, Sniderman AD, Cianflone K, et al. Hyperapobetalipoproteinemia: plasma lipoprotein responses to oral fat load. Arteriosclerosis 1986; 6(3): 297-304.
120. Castro Cabezas M, de Bruin TW, de Valk HW, et al. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest 1993; 92(1): 160-8.
121. Cianflone K, Zhang XJ, Genest J Jr, Sniderman AD. Plasma acylation stimulating protein in coronary artery disease. Arterioscler Thromb Vasc Biol 1997; (in press).
122. Saxena U, Goldberg IJ. Interaction of lipoprotein lipase with glycosaminoglycans and apolipoprotein C-II: Effects of free fatty acids. Biochim Biophys Acta 1990; 1043: 161-8.
123. Sniderman A, Cianflone K. Substrate delivery as a determinant of hepatic apoB secretion. Arteriocler Thromb 1993; 13(5): 629-36.
124. Gibbons GF. Assembly and secretion of hepatic very-low-density lipoprotein. Biochem J 1990; 268: 1-13.
125. Dixon JL, Ginsberg HN. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: Information obtained from cultured liver cells. J Lipid Res 1993; 34: 167-79.